Combination immunotherapy with anti-VEGF therapies have been used in the treatment of advanced renal cell cancer (RCC) [82, 83] and non-small cell lung cancer [84] with improvements in survival in these tumor types. The gene discussed is VEGFA; the disease is renal cell adenocarcinoma.